Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Lymphoid 1Head & Neck 1

Conditions

Mucositis 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Radiotherapy 9naloxegol 7Metformin 7Surveys and Questionnaires 6Cisplatin 6Exenatide 4Vitamin D 3Sugars 3Fibroblast Growth Factor 7 3Water 2Therapeutics 2Testosterone 2Resistance Training 2Radiation 2Nutrition Assessment 2Methods 2Low-Level Light Therapy 2Injections 2Fentanyl 2Drug Therapy 2Dexamethasone 2Cryotherapy 2Calcium Dobesilate 2Anastrozole 2prucalopride 1peppermint oil 1penclomedine 1pegfilgrastim 1oxycodone-acetaminophen 1methylnaltrexone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pain Management × Other × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡